By Jacki Chou, Caroline Huber, Jennifer Millard
PRECISIONheor
As employers consider including COVID-19 testing as part of their reopening plans, Precision experts Jacquelyn Chou, Caroline Huber and Jennifer Millard discuss the two key issues that must be resolved before antibody testing can be truly useful for an employer.
Congratulations to Precision’s Jason Shafrin, Dr. Bapu Jena, and Elizabeth Oyekan who presented a well-attended virtual panel at #ISPOR2020
Congratulations to Precision’s Jason Shafrin, Dr. Bapu Jena, and Elizabeth Oyekan who presented a well-attended virtual panel at #ISPOR2020: “Will APMs Incentivize High-Value Medications?”
The coronavirus disease 2019 (COVID-19) pandemic has exposed and further exacerbated the fractures in our healthcare and social delivery systems.
There has never been a more urgent time for manufacturers to develop or evolve their strategic frameworks to address adverse social risk factors that have been exacerbated by the COVID-19 pandemic and contribute to health inequities glaringly evident during the pandemic. This article describes strategies pharmaceutical manufacturers must adopt to address social determinants of health and population health management challenges, supporting patients, families, and clinicians during this pandemic and beyond.
Read the full article here!
COVID-19 has certainly impacted everyone’s day-to-day life, and payers operating within the market access landscape are no exception. In our latest All Access newsletter, we asked our advisors how and what payers are prioritizing during the struggles of COVID-19. Get your complimentary copy here.
How can the COVID-19 pandemic improve vaccination rates?
Everyone is impacted by COVID-19, meaning that everyone can relate to messaging based on it. Precision’s Jeremy Schafer and Deborah Lotterman discuss how to use vaccine messaging based on our shared coronavirus experiences to improve vaccination rates and educate the public on their importance.
Read the full article here!
By James Baumgarden, PhD
PRECISIONheor
CAR-T therapy breaks a pattern of stagnant efficacy growth in pharmaceutical innovation. A new CAR-T therapy study, by Precision’s James Baumgarden and his study co-authors, demonstrates significantly greater incremental effectiveness and similar cost–effectiveness to previous anticancer treatments.
PRECISIONvalue advances market-access marketing through experiential strategy, effective value demonstration, and market-access-focused resource development.
By James Baumgarden, PhD
PRECISIONheor
CAR-T therapy breaks a pattern of stagnant efficacy growth in pharmaceutical innovation. A new CAR-T therapy study, by Precision’s James Baumgarden and his study co-authors, demonstrates significantly greater incremental effectiveness and similar cost–effectiveness to previous anticancer treatments.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
